Headquartered in Boston, MA Fiscal year ends December NYSE: DNA ginkgo.bio
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) builds tools that make biology easier to engineer. The company operates autonomous laboratories that replace manual laboratory work with robotics, significantly improving the productivity of scientists. Its flagship autonomous lab, Nebula, houses more than 100 robots capable of running experiments around the clock. Ginkgo offers its in-house autonomous lab capabilities as a 'Cloud Lab' through its Datapoints and Solutions contract research services. The company operates as a single segment, Cell Engineering, serving pharmaceutical, industrial biotechnology, and government customers. Ginkgo is also building autonomous lab infrastructure for U.S. government agencies and universities under NSF and other federal programs, positioning itself as a provider of next-generation R&D infrastructure for onshoring American scientific research and drug discovery. Updated
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Dumpster diving can be a lucrative pastime. One man’s trash is another’s treasure. That holds true in investing, too, but the risks are also the same: you might find a nugget of…
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Tuesday's additional top analyst upgrades and downgrades were on Bank of New York Mellon, Butterfly Network, Etsy, Ginkgo Bioworks, Illumina, Poshmark and more.
Wednesday’s additional top analyst upgrades and downgrades included Canadian National Railway, Carrier Global, Century Aluminum, Expedia, Ginkgo Bioworks, U.S. Foods, Visa, Welltower and more.
Wednesday's top analyst upgrades and downgrades included Adobe, Amazon.com, Carnival, Chewy, Fiserv, Ginkgo Bioworks, Global Payments, Nvidia, Oracle, Procter & Gamble, SentinelOne, Walmart and Workday.
Thursday's top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi Technologies.
Tuesday afternoon's top analyst upgrades and downgrades included Coupa Software, Ginkgo Bioworks, Enterprise Products Partners and Intuit.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 2.1 million shares of Ginkgo Bioworks on January 6.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 750,000 shares of Ginkgo Bioworks on December 14.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought nearly 1.5 million shares of Ginkgo Bioworks on December 1.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 8 million shares of Ginkgo Bioworks on October 6.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) builds tools that make biology easier to engineer. The company operates autonomous laboratories that replace manual laboratory work with robotics, significantly improving the productivity of scientists.
The Wall Street consensus 12-month price target for DNA is $7.00.
